Research programme: eryminase therapeutics - ERYTECH Pharma

Drug Profile

Research programme: eryminase therapeutics - ERYTECH Pharma

Alternative Names: ERY-ADI; eryadi; eryminase programme; Gr-RNAi

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ERYtech Pharma
  • Developer ERYtech Pharma; Queens University
  • Class Antineoplastics; Enzymes
  • Mechanism of Action Amino-acid-modulators; Arginase modulators; Cytokine inhibitors; Macrophage inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hyperargininemia
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
  • 17 Jul 2017 ERYTECH and Queen's University agree to co-develop eryminase therapeutics for Hyperargininemia
  • 17 Jul 2017 Preclinical trials in Hyperargininemia in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top